RVMD – Revolution Medicines, Inc.
Revolution Medicines, Inc.RVMD
$39.95Name : Revolution Medicines, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $7,441,166,848.00
EPSttm : -4.01
Revolution Medicines, Inc.
$39.95
4.61%$1.93Float Short %
10.22
Margin Of Safety %
Put/Call OI Ratio
0.87
EPS Next Q Diff
-0.04
EPS Last/This Y
-1.08
EPS This/Next Y
-0.32
Price
39.95
Target Price
72.45
Analyst Recom
1.08
Performance Q
-3.62
Relative Volume
0.84
Beta
1.13
Ticker: RVMD
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | RVMD | 36.46 | 1.47 | 0.00 | 14865 |
| 2025-04-15 | RVMD | 36.3 | 1.47 | 0.00 | 14892 |
| 2025-04-16 | RVMD | 36.2 | 1.45 | 0.00 | 14984 |
| 2025-04-17 | RVMD | 36.8 | 1.37 | 0.07 | 15322 |
| 2025-04-18 | RVMD | 36.76 | 1.37 | 0.07 | 15322 |
| 2025-04-21 | RVMD | 36.56 | 1.38 | 0.26 | 15350 |
| 2025-04-22 | RVMD | 36.85 | 1.37 | 0.06 | 15384 |
| 2025-04-23 | RVMD | 37.41 | 1.37 | 0.03 | 15386 |
| 2025-04-24 | RVMD | 38.63 | 1.37 | 0.03 | 15416 |
| 2025-04-25 | RVMD | 38.77 | 1.2502102607233 | 0.5972850678733 | 16053 |
| 2025-04-28 | RVMD | 41.47 | 1.2113233287858 | 1.0787508486083 | 16209 |
| 2025-04-29 | RVMD | 40.67 | 1.24 | 1.42 | 18877 |
| 2025-04-30 | RVMD | 40.54 | 1.26 | 3.07 | 19848 |
| 2025-05-01 | RVMD | 40.63 | 1.20 | 1.22 | 19626 |
| 2025-05-02 | RVMD | 40.72 | 1.06 | 1.52 | 20414 |
| 2025-05-05 | RVMD | 39.82 | 1.00 | 0.18 | 20342 |
| 2025-05-06 | RVMD | 37.44 | 0.99 | 0.69 | 20406 |
| 2025-05-07 | RVMD | 37.64 | 0.99 | 0.00 | 20418 |
| 2025-05-08 | RVMD | 41.91 | 0.99 | 0.07 | 20468 |
| 2025-05-09 | RVMD | 40.45 | 0.98 | 0.00 | 20577 |
| 2025-05-12 | RVMD | 41.9 | 0.89 | 0.08 | 21615 |
| 2025-05-13 | RVMD | 39.97 | 0.87 | 0.10 | 21864 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | RVMD | 36.47 | -50.7 | -310.2 | -4.48 |
| 2025-04-15 | RVMD | 36.32 | -50.8 | -274.4 | -4.48 |
| 2025-04-16 | RVMD | 36.23 | -50.8 | -276.7 | -4.48 |
| 2025-04-17 | RVMD | 36.76 | -50.8 | -302.3 | -4.48 |
| 2025-04-18 | RVMD | 36.76 | -50.8 | -280.3 | -4.48 |
| 2025-04-21 | RVMD | 36.56 | -50.8 | -272.6 | -4.48 |
| 2025-04-22 | RVMD | 36.86 | -50.8 | -291.7 | -4.48 |
| 2025-04-23 | RVMD | 37.44 | -50.8 | -302.4 | -4.48 |
| 2025-04-24 | RVMD | 38.55 | -50.8 | -321.8 | -4.48 |
| 2025-04-25 | RVMD | 38.77 | -50.8 | -287.0 | -4.48 |
| 2025-04-28 | RVMD | 41.47 | -50.8 | -376.4 | -4.48 |
| 2025-04-29 | RVMD | 40.67 | -50.8 | -254.2 | -4.48 |
| 2025-04-30 | RVMD | 40.38 | -50.8 | -270.6 | -4.48 |
| 2025-05-01 | RVMD | 40.64 | -50.8 | -289.0 | -4.48 |
| 2025-05-02 | RVMD | 40.72 | -50.8 | -282.8 | -4.48 |
| 2025-05-05 | RVMD | 39.79 | -50.8 | -249.4 | -4.48 |
| 2025-05-06 | RVMD | 37.44 | -50.8 | -199.3 | -4.48 |
| 2025-05-07 | RVMD | 37.66 | -50.8 | -288.4 | -4.48 |
| 2025-05-08 | RVMD | 41.91 | -50.8 | -438.2 | -4.48 |
| 2025-05-09 | RVMD | 40.43 | -40.5 | -134.5 | -4.63 |
| 2025-05-12 | RVMD | 41.88 | -40.5 | -227.2 | -4.63 |
| 2025-05-13 | RVMD | 39.95 | -38.9 | -137.0 | -4.66 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | RVMD | 4.49 | 15.39 | 10.02 |
| 2025-04-15 | RVMD | 4.49 | 15.39 | 10.02 |
| 2025-04-16 | RVMD | 4.92 | 15.39 | 10.02 |
| 2025-04-17 | RVMD | 4.99 | 15.39 | 10.02 |
| 2025-04-18 | RVMD | 4.99 | 15.39 | 10.02 |
| 2025-04-21 | RVMD | 4.99 | 15.30 | 10.02 |
| 2025-04-22 | RVMD | 4.99 | 15.30 | 10.02 |
| 2025-04-23 | RVMD | 4.99 | 15.30 | 10.02 |
| 2025-04-24 | RVMD | 4.99 | 15.30 | 10.02 |
| 2025-04-25 | RVMD | 4.99 | 15.30 | 10.02 |
| 2025-04-28 | RVMD | 4.99 | 15.28 | 10.16 |
| 2025-04-29 | RVMD | 4.99 | 15.28 | 10.16 |
| 2025-04-30 | RVMD | 4.99 | 15.28 | 10.16 |
| 2025-05-01 | RVMD | 4.99 | 15.28 | 10.16 |
| 2025-05-02 | RVMD | 4.99 | 15.28 | 10.16 |
| 2025-05-05 | RVMD | 5.02 | 16.58 | 10.16 |
| 2025-05-06 | RVMD | 5.34 | 16.58 | 10.16 |
| 2025-05-07 | RVMD | 5.33 | 16.58 | 10.14 |
| 2025-05-08 | RVMD | 5.33 | 16.58 | 10.14 |
| 2025-05-09 | RVMD | 5.35 | 16.58 | 10.14 |
| 2025-05-12 | RVMD | 5.35 | 13.91 | 10.22 |
| 2025-05-13 | RVMD | 5.35 | 13.91 | 10.22 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.13
Avg. EPS Est. Current Quarter
-1.13
Avg. EPS Est. Next Quarter
-1.17
Insider Transactions
5.35
Institutional Transactions
13.91
Beta
1.13
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
25
Sentiment Score
69
Actual DrawDown %
36
Max Drawdown 5-Year %
-73.3
Target Price
72.45
P/E
Forward P/E
PEG
P/S
P/B
3.58
P/Free Cash Flow
EPS
-4
Average EPS Est. Cur. Y
-4.66
EPS Next Y. (Est.)
-4.98
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.84
Return on Equity vs Sector %
-57.3
Return on Equity vs Industry %
-40.3
EPS 1 7Days Diff
-0.2
EPS 1 30Days Diff
-0.18
EBIT Estimation
-137
Revolution Medicines, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 616
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
stock quote shares RVMD – Revolution Medicines, Inc. Stock Price stock today
news today RVMD – Revolution Medicines, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RVMD – Revolution Medicines, Inc. yahoo finance google finance
stock history RVMD – Revolution Medicines, Inc. invest stock market
stock prices RVMD premarket after hours
ticker RVMD fair value insiders trading